August 2026: MHRA Orders Six Devices Lacking Valid UKCA/CE Conformity Markings Removed from Use and Quarantined — All Manufacturers Are Indian Companies

What Happened

On 10 August 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published Device Safety Information DSI/2026/007, stating that a number of medical devices have been supplied on the UK market in a manner that does not comply with the UK Medical Devices Regulations 2002 (UK MDR 2002) or the EU Medical Devices Regulation (EU) 2017/745 (EU MDR). MHRA stated that it has not identified any specific defect, performance issue or safety signal in these products; however, because they lack the UKCA or CE device certification required for lawful supply in the UK market, their conformity assessment, quality management system, safety, sterility status and performance cannot be adequately assured.

Six Affected Products and Their Manufacturers

• VAKU-8 blood collection / infusion / scalp vein needle set — Hindustan Syringes & Medical Devices Ltd
• Bipson's sterile gauze swabs — Bipson Surgical Private Ltd
• Technocut surgical blades — HMD Healthcare India Pvt. Ltd. (formerly Niraj Industries Pvt. Ltd.)
• Romsons alcohol swabs — Romsons Group Private Ltd
• Medi Grip antimicrobial adhesive bandages — Precision Coatings (P) Ltd
• Bone marrow biopsy needles — Meditech Devices Pvt. Ltd.

The document states that the affected lot range is All lots.

Scope of Application and Official Requirements

These devices may be used in a range of clinical settings, including blood collection and infusion, surgical procedures, biopsy procedures, wound care, and skin preparation / disinfection. MHRA's requirements for healthcare organisations include the following:

• Immediately stop using and supplying the named products, and place all remaining stock in quarantine.
• Select and use compliant alternative products.
• Retain the affected devices pending further instruction from MHRA.
• Notify MHRA that the organisation holds affected devices by emailing devices.compliance@mhra.gov.uk, quoting the DSI number (DSI/2026/007).

Healthcare organisations must also ensure that relevant staff receive this Device Safety Information and understand the actions required, and must report suspected or actual adverse incidents through the channel applicable in their region.

For distributors, MHRA requires the following:

• Identify affected devices within their possession or control.
• Stop further supply.
• If they believe they have received, supplied or distributed affected devices, notify MHRA immediately via the mailbox above and provide known downstream distribution information.
• Assist with traceability as requested by MHRA.
• Retain customer records for the affected devices.
• Notify customers who may have received affected stock.

The document does not include any additional advice directed at patients.

Why Devices Can Be Removed from Use Despite Having "No Defect"

The key point of this document is not a specific failure mode but the absence of a compliant evidence chain. MHRA explicitly states that no specific device defect or safety signal has been identified, which can easily be misread as "no problem, they can still be used." The regulatory conclusion, however, is that these products have not gone through the conformity assessment route required for placing them on the UK market; consequently, their quality management system, sterility assurance and performance claims cannot be confirmed. The risk cannot be ruled out — it can only be judged as unverifiable.

In other words, this action addresses market authorisation compliance status rather than a single-batch quality incident. This also explains why the measure is "remove from use and place in quarantine" rather than a simple return or replacement: until the authorities issue further instructions, the products and the distribution chain need to be frozen to support traceability.

Source Boundaries

The official information underlying this analysis comprises the original DSI/2026/007 page published by MHRA on GOV.UK and the downloadable PDF of the same document. Both pages state a publication date of 10 August 2026. The same DSI also appears in MHRA's Safety Roundup: August 2026. The document does not disclose the specific quantities of affected products in circulation in the UK, details of distribution regions, or a timetable for further handling; this information was not public at the time of verification, and no inference is made here.

Sources and Scope of Verification

Source: Medicines and Healthcare products Regulatory Agency (MHRA) — Devices supplied without valid UKCA/CE conformity markings or certification: remove from use and place in quarantine (DSI/2026/007), published 10 August 2026.

• MHRA — DSI/2026/007 on GOV.UK: https://www.gov.uk/drug-device-alerts/devices-supplied-without-valid-ukca-slash-ce-conformity-markings-or-certification-remove-from-use-and-place-in-quarantine-dsi-slash-2026-slash-007
• MHRA — DSI/2026/007 original PDF, 10 August 2026: https://assets.publishing.service.gov.uk/media/6a746350ff25cc81486b244e/Devices_supplied_without_valid_UKCA_CE_conformity_markings_or_certification_-_remove_from_use_and_place_in_quarantine_DSI-20260-007.pdf
• MHRA — MHRA Safety Roundup: August 2026 (includes DSI/2026/007): https://assets.publishing.service.gov.uk/media/6a8d6639f5b35599aec18cec/MHRA_Safety_Roundup_-_August_2026.pdf

Scope of verification and access date: This verification reviewed the official GOV.UK page for DSI/2026/007 and the corresponding PDF, together with the MHRA Safety Roundup for August 2026; the access date was 13 October 2026 (Beijing time). The institution names, product list, lot range and required actions cited are based on the content stated on those pages.

Applicability note: This article is an interpretation of publicly available regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The official text prevails, and the information may change with subsequent official updates.

AIMEILI Regulatory Interpretation

DSI/2026/007 is an enforcement action grounded in market-access compliance rather than a product-liability or field-safety event. Three regulatory features distinguish it from a conventional recall.

First, the trigger is the absence of a valid conformity assessment route. For the UK market, devices must carry either UKCA marking under UK MDR 2002 or, under the applicable transitional arrangements, CE marking under EU MDR 2017/745. Where neither is supported by valid certification, the device has no lawful basis for supply, regardless of whether any batch-level nonconformity has been observed. Regulators treat the missing quality management system (QMS) oversight, sterility assurance and technical documentation as an unquantified risk that cannot be mitigated by post-market evidence.

Second, the required action is preservation rather than disposal. Quarantine plus retention pending MHRA instruction is designed to maintain the chain of custody for traceability, and to allow the authority to determine next steps once the compliance position of each product is clarified. Distributors are consequently expected to reconstruct downstream distribution records and proactively notify customers — obligations that sit with economic operators, not with the manufacturer alone.

Third, the action is not limited to a single manufacturer, product family or risk class. The six products span low-risk consumables (alcohol swabs, gauze), procedure-specific instruments (surgical blades, biopsy needles) and higher-risk device sets (blood collection, infusion and scalp vein needle sets), all from Indian manufacturers. This suggests a systematic compliance gap in the evidence chain for UK market entry, rather than an isolated quality deviation.

Business Impact

• Supply continuity for UK customers: Healthcare providers and distributors holding these products must source compliant alternatives immediately. For blood collection and infusion sets and biopsy needles, substitution may involve clinical evaluation and product qualification, so lead times should be anticipated.
• Stock at risk across the channel: Because the affected lot range is "All," every unit of the named products held by UK economic operators is potentially affected, including stock already delivered to end users. Distributors should quantify exposure and freeze movement now.
• Exporters without UKCA/CE certification: Manufacturers supplying the UK without valid certification face removal from the market regardless of product quality. Companies relying on self-declaration or on ceasing documentation for Class I or general device categories should reconcile their classification and conformity route against UK MDR 2002 before further shipments.
• Economic operator accountability: UK Responsible Persons, importers and distributors must be able to evidence traceability and to notify customers promptly. Where the manufacturer is overseas, the UK Responsible Person's record-keeping and communication arrangements become the practical control point.
• Regulatory signalling: This DSI indicates continued MHRA scrutiny of unmarked or uncertified devices entering the UK market, and reinforces that compliance status — not only adverse event data — is an enforcement trigger. Firms should review UK technical documentation, certification validity and labelling before the next shipment cycle.

Recommended Actions for Stakeholders

• Confirm whether any of the six named products or their lot numbers are held, supplied or in transit, and quarantine all affected stock.
• Notify MHRA at devices.compliance@mhra.gov.uk, quoting DSI/2026/007, if affected devices are held or have been distributed.
• Advance traceability reconstruction and customer notification, and retain records for MHRA follow-up.
• Qualify compliant alternatives and update approved supplier lists and contractual quality requirements.
• For manufacturers, verify that UKCA or CE certification is valid, correctly scoped and maintained, and that technical documentation and QMS evidence support the claimed classification.

Source Information

Medicines and Healthcare products Regulatory Agency (MHRA), 10 August 2026.